+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Coronavirus Disease 2019 (COVID-19) Sector Forecast: Analyst Consensus Sales Forecast

  • ID: 5024214
  • Report
  • April 2020
  • Region: Global
  • 27 pages
  • GlobalData
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • CanSino Biologic Inc.
  • Cytodyn Inc.
  • Gilead Sciences Inc.
  • MORE
Coronavirus Disease 2019 (COVID-19) Sector Forecast: Analyst Consensus Sales Forecast

Summary

This report contains a summary of the analyst consensus forecasts available in the Pharma Intelligence Center Drug Sales and Analyst Consensus Database for the Indication COVID-19. Despite the rapid development of COVID-19 therapies being developed the majority of the COVID-19 pipeline is in early stage development so there are few forecasts available. Currently there are three drugs indicated for COVID-19 which have analyst consensus forecasts available.

Scope

This 27-page report gives important, expert insight you won’t find in any other source. 7 figures throughout the report illustrate major points and trends in COVID sales forecasts and company pipelines. This report is required reading for -
  • Investors that want to understand how COVID-19 has impacted Drug Revenues in the biopharmaceutical industry as well as identifying companies to invest in
  • Companies that are interested in entering the COVID-19 disease space
  • Large pharma companies with investment groups or BD teams looking for partnership opportunities in the COVID-19 disease space
Reasons to Buy
  • Analysis of COVID-19 analyst consensus sales forecasts
  • Overview of Pipeline portfolio of companies involved in COVID-19 disease space
  • Detailed Analysis of how COVID-19 have affected analyst consensus sales forecasts for previously forecasted Drugs
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • CanSino Biologic Inc.
  • Cytodyn Inc.
  • Gilead Sciences Inc.
  • MORE
1 COVID-19 Global Analyst Consensus Sales Forecast

2 Gilead Sciences Inc.
2.1 Gilead Sciences’ Pipeline
2.2 Global Analyst Consensus Sales Forecast - Gilead Sciences’ Remdesivir

3 CanSino Biologic Inc.
3.1 CanSino Biologic Pipeline
3.2 Global Analyst Consensus Sales Forecast - CanSino Biologic’s COVID-19 Vaccine

4 Cytodyn Inc.
4.1 Global Analyst Consensus Sales Forecast - Cytodyn’s Leronlimab
4.2 Archived Global Analyst Consensus Sales Forecast - Cytodyn’s Leronlimab

5 Key Findings

6 Appendix
6.1 Methodology
6.2 Related Reports
6.3 About the Authors
6.4 About the Publisher
6.5 Contact the Publisher
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Gilead Sciences Inc.
  • CanSino Biologic Inc.
  • Cytodyn Inc.
Note: Product cover images may vary from those shown
Adroll
adroll